Fate Therapeutics, Inc.NASDAQ: FATE

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

· Issued by Fate Therapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

Fate Therapeutics, a clinical-stage biopharmaceutical company developing immune-cell therapies made from lab-made stem cells for cancer and autoimmune diseases, said its management will take part in two investor conferences in the fourth quarter of 2026.

Key details

  • 2026 Jefferies Global Healthcare Conference in London, UK, from November 16 to 19, 2026.
  • Piper Sandler 38th Annual Healthcare Conference in New York, NY, from December 1 to 3, 2026.
  • When available, a live webcast will be offered on the company's investor website, with an archived replay available for 30 days after each event.

What’s still pending

  • The company may take part in a presentation or a fireside chat (an informal on-stage interview) at these conferences.
  • Live webcasts will be offered only when available.

6ix AI wrote this summary from the release below and checked it against the release.

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026.

2026 Jefferies Global Healthcare Conference

Location: London, UK

Date: November 16th – 19th

Piper Sandler 38th Annual Healthcare Conference

Location: New York, NY

Date: December 1st – 3rd

The Company may participate in a presentation or a fireside chat at these conferences. When available, a live webcast will be accessible under “Events & Presentations” on the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 30 days following the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:

Ryan Douglas
Fate Therapeutics, Inc.
[email protected]

Fate Therapeutics, Inc. on 6ix

Story so far

Earlier from Fate Therapeutics

Later from Fate Therapeutics

All Fate Therapeutics news releases